Mineralys Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on Wednesday, February 12, 2025
Mineralys Therapeutics (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines for hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other aldosterone-related diseases, has scheduled its fourth quarter and full year 2024 financial results announcement. The results will be released before market open on Wednesday, February 12, 2025.
The company will host a conference call at 8:30 a.m. ET on the same day, accessible via domestic (1-800-717-1738) and international (1-646-307-1865) dial-in numbers. A live webcast will be available through the Investor Relations section of the company's website.
Mineralys Therapeutics (NASDAQ: MLYS), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di farmaci per l'ipertensione, la malattia renale cronica (CKD), l'
L'azienda terrà una conferenza telefonica alle 8:30 a.m. ET dello stesso giorno, accessibile tramite numeri di accesso nazionali (1-800-717-1738) e internazionali (1-646-307-1865). Una diretta web sarà disponibile attraverso la sezione Relazioni con gli Investitori del sito web dell'azienda.
Mineralys Therapeutics (NASDAQ: MLYS), una empresa biofarmacéutica en etapa clínica centrada en desarrollar medicamentos para la hipertensión, la enfermedad renal crónica (ERC), la apnea obstructiva del sueño (AOS) y otras enfermedades relacionadas con la aldosterona, ha programado el anuncio de sus resultados financieros del cuarto trimestre y del año completo 2024. Los resultados se darán a conocer antes de la apertura del mercado el miércoles 12 de febrero de 2025.
La empresa llevará a cabo una teleconferencia a las 8:30 a.m. ET el mismo día, accesible a través de números de marcación nacional (1-800-717-1738) e internacional (1-646-307-1865). Se dispondrá de una transmisión en vivo a través de la sección de Relaciones con Inversores del sitio web de la empresa.
미네랄리스를 치료제(Mineralys Therapeutics) (NASDAQ: MLYS)는 고혈압, 만성 신장 질환 (CKD), 폐쇄성 수면 무호흡증 (OSA) 및 기타 알도스테론 관련 질환을 위한 의약품 개발에 집중하는 클리니컬 스테이지 생물 제약 회사로, 2024년 4분기 및 연간 재무 결과 발표 일정을 잡았습니다. 결과는 2025년 2월 12일 수요일 시장 개장 전에 발표될 예정입니다.
회사는 같은 날 오전 8시 30분 ET에 전화 회의를 개최하며, 국내(1-800-717-1738) 및 국제(1-646-307-1865) 다이얼 인 번호로 접근할 수 있습니다. 회사 웹사이트의 투자자 관계 섹션을 통해 생중계 웹캐스트가 제공될 것입니다.
Mineralys Therapeutics (NASDAQ: MLYS), une entreprise biopharmaceutique en phase clinique axée sur le développement de médicaments pour l'hypertension, la maladie rénale chronique (MRC), l'
L'entreprise tiendra une conférence téléphonique à 8h30 ET le même jour, accessible via des numéros d'appel nationaux (1-800-717-1738) et internationaux (1-646-307-1865). Un webinaire en direct sera disponible par le biais de la section Relations Investisseurs du site internet de l'entreprise.
Mineralys Therapeutics (NASDAQ: MLYS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung von Medikamenten für Hypertonie, chronische Nierenerkrankung (CKD), obstruktive Schlafapnoe (OSA) und andere aldosteronbezogene Erkrankungen konzentriert, hat die Bekanntgabe seiner Finanzzahlen für das vierte Quartal und das gesamte Jahr 2024 geplant. Die Ergebnisse werden vor der Markteröffnung am Mittwoch, den 12. Februar 2025 veröffentlicht.
Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz abhalten, die über nationale (1-800-717-1738) und internationale (1-646-307-1865) Einwahlnummern zugänglich ist. Ein Live-Webcast wird über den Bereich Investor Relations auf der Unternehmenswebsite verfügbar sein.
- None.
- None.
RADNOR, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2024, before the financial markets open on Wednesday, February 12, 2025.
| Wednesday, February 12th @ 8:30 a.m. ET | |
| Domestic: | 1-800-717-1738 |
| International: | 1-646-307-1865 |
| Webcast: | Link |
A live webcast of the conference call may also be found on the “News & Events” page in the Investor Relations section of the Mineralys Therapeutics website.
About Mineralys Therapeutics
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD, OSA and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension, CKD and OSA. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn and Twitter.
Contact:
Investor Relations
investorrelations@mineralystx.com
Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com
FAQ
When will Mineralys Therapeutics (MLYS) release Q4 and full year 2024 earnings?
How can investors access the MLYS Q4 2024 earnings call?
What therapeutic areas does Mineralys Therapeutics (MLYS) focus on?
